| Literature DB >> 28706097 |
Anne Kouvonen1,2,3, Minna Mänty4, Tea Lallukka4,5, Olli Pietiläinen4, Eero Lahelma4, Ossi Rahkonen4.
Abstract
OBJECTIVES: To investigate whether changes in psychosocial and physical working conditions are associated with subsequent psychotropic medication in ageing employees.Entities:
Keywords: longitudinal studies; mental health; work stress
Mesh:
Substances:
Year: 2017 PMID: 28706097 PMCID: PMC5734573 DOI: 10.1136/bmjopen-2016-015573
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Distribution of demographics (phase 1; 2000–2002), working conditions (phase 1–phase 2; 2007) and any psychotropic medication* between phase 2 and 2013, the Helsinki Health Study, Finland (%) (n=3587)
| No medication, n (%) | Medication, n (%) | Mean DDDs (SD)† | |
| Sex | |||
| Women | 2034 (71) | 847 (29) | 496.0 (773.3) |
| Men | 545 (77) | 161 (23) | 487.1 (793.0) |
| Age (years) | |||
| 40 | 632 (72) | 247 (28) | 587.5 (949.9) |
| 45 | 636 (68) | 298 (32) | 537.6 (788.6) |
| 50 | 664 (72) | 259 (28) | 429.5 (660.0) |
| 55 | 627 (76) | 196 (24) | 391.2 (627.2) |
| 60 | 20 (71) | 8 (29) | 666.2 (818.6) |
| Job control | |||
| High–high | 1075 (73) | 402 (27) | 453.2 (806.6) |
| High–low | 358 (71) | 148 (29) | 458.3 (793.9) |
| Low–high | 300 (72) | 117 (28) | 541.5 (761.1) |
| Low–low | 846 (71) | 341 (29) | 543.1 (749.3) |
| Job demands | |||
| Low–low | 554 (74) | 304 (26) | 411.6 (647.4) |
| Low–high | 419 (72) | 165 (28) | 476.1 (716.0) |
| High–low | 432 (72) | 169 (28) | 463.7 (694.2) |
| High–high | 844 (70) | 370 (30) | 585.1 (915.3) |
| Physical work load | |||
| Low–low | 1718 (73) | 633 (27) | 500.2 (767.4) |
| Low–high | 248 (869) | 112 (31) | 455.4 (679.6) |
| High–low | 255 (71) | 104 (29) | 428.1 (704.8) |
| High–high | 358 (69) | 159 (31) | 543.4 (909.2) |
*Participants with psychotropic medication purchases in 3 months preceding phase 2 were excluded.
†Mean of DDDs and their SDs in those who had psychotropic medication purchases during the follow-up.
DDDs, defined daily doses.
Age and sex-adjusted HRs and their 95%CIs for associations of changes in working conditions between phase 1 (2000–2002) and phase 2 (2007) and subsequent psychotropic medication between phase 2 and the end of 2013, the Helsinki Health Study, Finland
| Any psychotropic | Antidepressants (N06A) | Anxiolytics (N05B) | Sedatives and hypnotics (N05C) (N=3808) | |||||||||
| n (cases) | HR | 95% CI | n (cases) | HR | 95% CI | n (cases) | HR | 95% CI | n (cases) | HR | 95% CI | |
| Job control | ||||||||||||
| High–high | 1477 (402) | 1.00 | Reference | 1499 (264) | 1.00 | Reference | 1573 (102) | 1.00 | Reference | 1559 (245) | 1.00 | Reference |
| High–low | 506 (148) | 1.08 | 0.90 to 1.31 | 518 (95) | 1.04 | 0.82 to 1.32 | 542 (43) | 1.22 | 0.86 to 1.74 | 532 (94) | 1.13 | 0.89 to 1.43 |
| Low–high | 417 (117) | 1.03 | 0.84 to 1.27 | 425 (80) | 1.06 | 0.83 to 1.36 | 457 (27) | 0.90 | 0.59 to 1.38 | 449 (91) | 1.33 | 1.04 to 1.69 |
| Low–low | 1187 (341) | 1.08 | 0.94 to 1.25 | 1218 (244) | 1.18 | 0.99 to 1.41 | 1295 (113) | 1.37 | 1.05 to 1.79 | 1268 (205) | 1.03 | 0.86 to 1.24 |
| Job demands | ||||||||||||
| Low–low | 1188 (304) | 1.00 | Reference | 1208 (205) | 1.00 | Reference | 1267 (83) | 1.00 | Reference | 1254 (185) | 1.00 | Reference |
| Low–high | 584 (165) | 1.09 | 0.90 to 1.32 | 598 (117) | 1.10 | 0.88 to 1.38 | 632 (45) | 1.05 | 0.73 to 1.52 | 619 (108) | 1.20 | 0.94 to 1.52 |
| High–low | 601 (169) | 1.09 | 0.91 to 1.32 | 610 (106) | 1.01 | 0.80 to 1.27 | 649 (41) | 0.96 | 0.66 to 1.39 | 639 (110) | 1.16 | 0.92 to 1.47 |
| High–high | 1214 (370) | 1.22 | 1.04 to 1.42 | 1244 (255) | 1.20 | 1.00 to 1.45 | 1319 (116) | 1.33 | 1.00 to 1.76 | 1296 (232) | 1.21 | 0.99 to 1.47 |
| Physical work load | ||||||||||||
| Low–low | 2351 (633) | 1.00 | Reference | 2390 (423) | 1.00 | Reference | 2508 (168) | 1.00 | Reference | 2480 (382) | 1.00 | Reference |
| Low–high | 360 (112) | 1.17 | 0.96 to 1.43 | 371 (78) | 1.17 | 0.92 to 1.49 | 400 (26) | 1.09 | 0.74 to 1.62 | 384 (74) | 1.32 | 1.04 to 1.69 |
| High–low | 359 (104) | 1.07 | 0.87 to 1.32 | 369 (63) | 0.93 | 0.71 to 1.21 | 396 (30) | 0.95 | 0.63 to 1.44 | 398 (80) | 1.25 | 0.96 to 1.60 |
| High–high | 517 (159) | 1.17 | 0.98 to 1.39 | 530 (119) | 1.30 | 1.06 to 1.59 | 563 (61) | 1.66 | 1.24 to 2.23 | 546 (99) | 1.22 | 0.98 to 1.52 |
Participants with psychotropic medication purchases in question (the medication groups were not mutually exclusive) in 3 months preceding phase 2 were excluded.
Age and sex-adjusted HRs and their 95% CIs for associations of changes in working conditions between phase 1 (2000–2002) and phase 2 (2007) and subsequent psychotropic medication between phase 2 and the end of 2013, the Helsinki Health Study, Finland
| Any psychotropic | Antidepressants (N06A) | Anxiolytics (N05B) | Sedatives and hypnotics (N05C) (N=3808) | |||||||||
| n (cases) | HR | 95 | n (cases) | HR | 95 | n (cases) | HR | 95 | n (cases) | HR | 95 | |
| Job control | ||||||||||||
| High–high | 1477 (402) | 0.92 | 0.80 to 1.07 | 1499 (264) | 085 | 0.71 to 1.01 | 1573 (102) | 0.73 | 0.56 to 0.96 | 1559 (245) | 0.97 | 0.81 to 1.17 |
| High–low | 506 (148) | 1.00 | 0.82 to 1.21 | 518 (95) | 0.88 | 0.70 to 1.12 | 542 (43) | 0.89 | 0.63 to 1.27 | 532 (94) | 1.09 | 0.86 to 1.40 |
| Low–high | 417 (117) | 0.95 | 0.77 to 1.18 | 425 (80) | 0.90 | 0.70 to 1.16 | 457 (27) | 0.66 | 0.43 to 1.00 | 449 (91) | 1.29 | 1.00 to 1.65 |
| Low–low | 1187 (341) | 1.00 | Reference | 1218 (244) | 1.00 | Reference | 1295 (113) | 1.00 | Reference | 1268 (205) | 1.00 | Reference |
| Job demands | ||||||||||||
| Low–low | 1188 (304) | 0.82 | 0.71 to 0.96 | 1208 (205) | 0.83 | 0.69 to 1.00 | 1267 (83) | 0.75 | 0.57 to 1.00 | 1254 (185) | 0.83 | 0.68 to 1.01 |
| Low–high | 584 (165) | 0.90 | 0.75 to 1.08 | 598 (117) | 0.91 | 0.73 to 1.14 | 632 (45) | 0.79 | 0.56 to 1.12 | 619 (108) | 0.99 | 0.79 to 1.25 |
| High–low | 601 (169) | 0.90 | 0.75 to 1.08 | 610 (106) | 0.84 | 0.67 to 1.05 | 649 (41) | 0.72 | 0.50 to 1.03 | 639 (110) | 0.96 | 0.77 to 1.21 |
| High–high | 1214 (370) | 1.00 | Reference | 1244 (255) | 1.00 | Reference | 1319 (116) | 1.00 | Reference | 1296 (232) | 1.00 | Reference |
| Physical work load | ||||||||||||
| Low–low | 2351 (633) | 0.85 | 0.72 to 1.02 | 2390 (423) | 0.77 | 0.63 to 0.95 | 2508 (168) | 0.60 | 0.45 to 0.81 | 2480 (382) | 0.82 | 0.66 to 1.03 |
| Low–high | 360 (112) | 0.91 | 0.71 to 1.17 | 371 (78) | 0.90 | 0.68 to 1.20 | 400 (26) | 0.66 | 0.43 to 1.02 | 384 (74) | 1.09 | 0.81 to 1.46 |
| High–low | 359 (104) | 1.00 | 0.78 to 1.27 | 369 (63) | 0.72 | 0.53 to 0.98 | 396 (30) | 0.57 | 0.36 to 0.90 | 398 (80) | 1.03 | 0.76 to 1.39 |
| High–high | 517 (159) | 1.00 | Reference | 530 (119) | 1.00 | Reference | 563 (61) | 1.00 | Reference | 546 (99) | 1.00 | Reference |
Participants with psychotropic medication purchases in question (the medication groups were not mutually exclusive) in 3 months preceding phase 2 were excluded.